Distribuzione geografica
Continente #
EU - Europa 3237
NA - Nord America 3224
AS - Asia 1060
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 7
AF - Africa 5
SA - Sud America 4
Totale 7546
Nazione #
US - Stati Uniti d'America 3212
GB - Regno Unito 1100
CN - Cina 957
IT - Italia 665
SE - Svezia 422
FR - Francia 336
IE - Irlanda 254
DE - Germania 134
FI - Finlandia 126
VN - Vietnam 67
UA - Ucraina 55
BE - Belgio 49
RU - Federazione Russa 40
IN - India 11
MK - Macedonia 11
CA - Canada 10
NL - Olanda 8
CH - Svizzera 7
EU - Europa 7
TR - Turchia 7
AU - Australia 6
JP - Giappone 6
ES - Italia 5
SD - Sudan 5
AT - Austria 3
CL - Cile 3
GR - Grecia 3
IR - Iran 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
DK - Danimarca 2
HK - Hong Kong 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
BD - Bangladesh 1
BR - Brasile 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
HU - Ungheria 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
TH - Thailandia 1
Totale 7546
Città #
Southend 987
Chandler 786
Woodbridge 382
Ann Arbor 374
Jacksonville 329
Dublin 254
Verona 163
Houston 147
Beijing 146
Wilmington 126
Lawrence 122
Princeton 122
Jinan 107
Nanjing 96
Ashburn 90
Hebei 88
Shenyang 85
Brussels 49
Tianjin 44
Dong Ket 43
Lancaster 43
Redwood City 42
Zhengzhou 41
Ningbo 40
Milan 39
Changsha 38
Haikou 37
Nanchang 37
Redmond 35
Hangzhou 31
Taiyuan 29
Taizhou 27
Fuzhou 21
Guangzhou 21
Dearborn 20
Falls Church 20
Jiaxing 19
Norwalk 18
Bologna 15
Catania 14
Clearwater 13
Lanzhou 13
Düsseldorf 11
Skopje 11
Auburn Hills 10
Boardman 10
Padova 10
Riva 10
Fairfield 9
Kemerovo 9
New York 9
Bisenti 7
Bolzano 7
Loreggia 7
Rome 7
Arco 6
Los Angeles 6
Catanzaro 5
Chicago 5
Dallas 5
Genova 5
Orzivecchi 5
Seriate 5
Fairport 4
Novokuznetsk 4
Phoenix 4
San Diego 4
Seattle 4
Segrate 4
Yonkers 4
Ardabil 3
Augusta 3
Boston 3
Brescia 3
Cleveland 3
Feltre 3
Helsinki 3
Jesi 3
Las Vegas 3
Littleton 3
Montréal 3
Murfreesboro 3
Olgiate Olona 3
Palena 3
Puxian 3
Saint Louis 3
San Francisco 3
Sydney 3
Toronto 3
Trondheim 3
Udine 3
Yicheng 3
Bari 2
Bratislava 2
Buffalo 2
Bussolengo 2
Cambridge 2
Canberra 2
Castelfiorentino 2
Castellana Grotte 2
Totale 5422
Nome #
Psicologia positiva e disabilità: affrontare le sfide del futuro nell'adulto con disabilità acquisita, cronica e progressiva 245
Gestione degli eventi avversi dei farmaci modificanti il decorso della malattia nella sclerosi multipla 165
Un caso di sclerosi multipla con esordio "tumor-like" e decorso benigno 161
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study 121
Two sisters with Leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's Syndrome? 111
A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. 110
Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study 106
Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. 100
QTc interval in patients with multiple sclerosis: an inference from the insula of Reil? 98
Levofloxacin-induced hemichorea-hemiballism in a patient with previous thalamic infarction 97
Risk factors for post-polio syndrome among an Italian population: a case-control study. 94
A Case-control study of myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis in Verona, Italy 94
A case of multifocal CIS with unusual MRI features suggestive of Balo's concentric sclerosis 92
Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder 91
Cognitive onset in multiple sclerosis 90
Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial 89
Intravenous immunoglobulin for post-polio syndrome: a randomized double-blind, placebo-controlled study 88
Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study. 85
An active case of radiologically isolated syndrome: from MRI detection to multiple sclerosis 85
The diagnosis of multiple sclerosis: pinpointing the concept of "no better explanation" 85
Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? 84
Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? 83
Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis 82
Regional distribution and evolution of grey matter changes in different MS phenotypes: a 5-year longitudinal study 81
HCV-related nervous system disorders. 78
Clinical and demographic predictors of response to first-line therapies in relapsing-remitting multiple sclerosis 78
A case of acute fulminant multiple sclerosis treated with alemtuzumab 77
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients 74
Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five years prospective study 73
Brentuximab vedotin: axonal microtubule's Apollyon 73
High-intensity robot-assisted hand training in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 73
Response to Nagai et al. 72
Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders 72
Physicochemical properties of Aβ peptides in cerebrospinal fluid of Alzheimer’s disease patients 71
A panel of exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS: does it add relevant information to usual work-up? 71
Assessment of outcome predictors in first-episode acute myelitis: a retrospective study of 53 cases. 70
Long lesions on initial spinal cord MRI predict a final diagnosis of acute disseminated encephalomyelitis versus multiple sclerosis in children 70
Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. 70
Epilepsy in multiple sclerosis: The role of temporal lobe damage 70
Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis 69
Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions 69
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis 69
An exploratory panel of cerebrospinal fluid biomarkers compared to standard diagnostic evaluation in initial demyelinating events suggestive of multiple sclerosis 68
Prognostic factors of acute partial transverse myelitis. 68
Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015 68
Long-term clinical, cognitive and MRI characteristics of patients with untreated benign multiple sclerosis: a natural history study 66
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 66
A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies 66
Long survival and clinical stability in Marburg's variant multiple sclerosis. 65
Acute cardiovascular dysfunction in multiple sclerosis: report of two cases and literature review 65
Two sisters with leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's syndrome? 65
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis 64
Early predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis 64
Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study 64
Increased cortical lesion load and CSF cytokines in oligoclonal band positive MS patients 64
Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study 64
Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. 63
Benign course of tumour-like multiple sclerosis. Report of five cases and literature review. 63
Prognostic indicators of “benign” clinical course in multiple sclerosis patients. 61
HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod 61
Increased cerebrospinal fluid cystatin C may predict disability after acute myelitis 60
Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. 59
Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. 59
Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis 59
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. 58
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure 58
Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis 58
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 56
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder 56
Effects of high-intensity robot-assisted training in hand function recovery and adl independence in individuals with multiple sclerosis: A randomized controlled single-blinded trial 55
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis 54
2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? 54
Tumor-like multiple sclerosis: three cases misdiagnosed as primary brain neoplasm 53
Characterization of Upper Limb Impairments at Body Function, Activity, and Participation in Persons With Multiple Sclerosis by Behavioral and EMG Assessment: A Cross-Sectional Study 53
Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. 52
Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status 52
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases 52
A bio-psycho-social co-created intervention for young adults with multiple sclerosis (ESPRIMO): rationale and study protocol for a feasibility study 52
"If you can't control the wind, adjust your sail": tips for post-pandemic benefit finding from young adults living with multiple sclerosis. A qualitative study 52
Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis 51
Insights for fostering resilience in young adults with multiple sclerosis in the aftermath of the COVID-19 emergency: an Italian survey 51
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date 50
Effects of high-intensity robot-assisted hand training on upper limb recovery and muscle activity in individuals with multiple sclerosis: a randomized, controlled, single-blinded trial 49
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 49
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 49
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: an Italian multi-centre study 47
Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis 46
Analisi delle alterazioni funzionali dell’arto superiore e dell’attività muscolare mediante emgs in pazienti con sclerosi multipla: uno studio “cross-sectional” 46
Demographic and clinical predictors of response to interferon beta and glatiramer acetate as first-line treatment for relapsing-remitting multiple sclerosis 45
Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis 45
Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD 45
Amyloid myopathy: an intriguing diagnosis 45
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives 45
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 44
Increase of CSF inflammatory profile in a case of highly active multiple sclerosis 44
Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? 43
Up-regulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients 43
Totale 7057
Categoria #
all - tutte 14585
article - articoli 13762
book - libri 0
conference - conferenze 287
curatela - curatele 0
other - altro 122
patent - brevetti 0
selected - selezionate 0
volume - volumi 414
Totale 29170

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201882 0000 00 00 0422020
2018/2019596 273219828 3026 15623 10251724
2019/20201005 115221955 18072 15330 5211491102
2020/20211169 14222379116 137103 2841 653510496
2021/20221177 9841831123 2723 1174 363274230
2022/20232118 153291212372 175483 39146 247000
Totale 7738